Celltrion has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion for an autoinjector presentation of SteQeyma, the company’s biosimilar to Janssen’s ustekinumab, for the European market.[3] This development represents a strategically significant milestone for the European biopharmaceutical landscape, as it expands the range of biosimilar administration formats available to healthcare providers and payers seeking cost-effective alternatives to reference biologics. From a B2B pharmaceutical perspective, this CHMP opinion is particularly important for stakeholders involved in contract manufacturing, pharmaceutical formulations, device–drug combination development, and procurement, as it underscores continued regulatory support in Europe for high-quality biosimilars integrated with advanced delivery devices.

The positive CHMP opinion covers SteQeyma autoinjector strengths of 45 mg/0.5 mL and 90 mg/1 mL, complementing the already approved SteQeyma portfolio that includes pre-filled syringes and vials for subcutaneous injection, as well as an intravenous formulation.[3] For hospital pharmacists, R&D device teams, and supply chain planners across Europe, the addition of an autoinjector format introduces new considerations in packaging machinery, labelling, cold chain logistics, and inventory management. Commercial teams and market access units at both originator and biosimilar companies will be closely assessing how expanded presentations may influence tendering strategies, formulary decisions, and real-world uptake in chronic inflammatory disease indications where ustekinumab is widely used.

From a manufacturing and technology standpoint, the SteQeyma autoinjector aligns with several key Pharmaceutical-Tech categories, particularly pharmaceutical formulations, pharmaceutical packaging machinery, pharmaceutical materials and components, and pharmaceutical quality assurance. Integration of a biologic into an autoinjector requires advanced primary container and device engineering, robust human factors studies, and stringent validation activities to ensure dose accuracy, reliability, and ease of use. For contract development and manufacturing organizations (CDMOs) and device-focused contract services providers operating in Europe, the move by Celltrion signals sustained demand for sophisticated combination product capabilities, including automated assembly lines, in-line inspection, and serialization-ready packaging configurations.

For payers and procurement professionals across European health systems, the CHMP’s positive stance on the SteQeyma autoinjector provides another tool to drive competition in the high-cost biologics segment. As national and regional tenders increasingly factor in device convenience, patient self-administration capability, and support services alongside price, biosimilar manufacturers are under pressure to match or exceed the usability profile of originator products. The SteQeyma autoinjector, by promising enhanced convenience and individualized treatment options, positions Celltrion to participate more competitively in hospital and retail tenders that prioritize both clinical and operational value. This may stimulate additional pipeline investment by other biosimilar developers into autoinjectors and connected devices tailored for the European market.

Logistics and supply chain teams will also need to adapt to the broadened SteQeyma presentation range. Each new device format introduces differentiated packaging dimensions, stability profiles, and handling instructions that must be integrated into cold chain storage and distribution systems. Wholesalers, specialty distributors, and third-party logistics providers servicing European markets will likely revisit their lane qualifications, packaging solutions, and temperature-monitoring protocols to accommodate growing portfolios of device-based biosimilars. In parallel, quality assurance and regulatory affairs teams at both Celltrion and its partners must ensure that pharmacovigilance systems and risk management plans adequately capture device-related events, not just drug-related safety signals.

Strategically, this CHMP opinion further consolidates Celltrion’s position as a major player in the European biosimilars sector, where the company already markets products such as infliximab (Remsima), rituximab (Truxima), and others.[3] By expanding SteQeyma into an autoinjector presentation, Celltrion strengthens its immunology franchise and demonstrates its capability to develop not only follow-on biologics but also patient-friendly administration platforms. For European R&D leaders and business development executives, this underlines the growing importance of device–drug integration, human-centered design, and lifecycle management as differentiating factors in a crowded biosimilar marketplace. It also opens avenues for potential partnerships in device design, real-world evidence generation, and digital adherence solutions associated with autoinjector use.

Regulatory teams across the EU will pay particular attention to how the EMA’s assessment of the SteQeyma autoinjector addresses issues such as comparability, device performance, usability testing, and risk mitigation. These regulatory precedents may inform future submissions for other biosimilar–autoinjector combinations and could shape guidance around human factors engineering, electronic instructions for use, and labelling requirements. For consultancy firms and management consulting providers specializing in legislation and regulatory compliance, the SteQeyma case offers a timely example to support clients in planning EU-compliant strategies for combination products, including integration with upcoming horizontal regulations on packaging, environmental impact, and digital health documentation.

Operationally, the launch of an autoinjector format typically triggers updates in training for nurses, pharmacists, and occasionally for patient education programs managed by manufacturers’ support services. While the end-user focus is on patients with chronic inflammatory diseases, the B2B implications are substantial for pharmaceutical training and development teams who design materials, e-learning modules, and competency assessments for healthcare professionals handling new devices. Additionally, pharmaceutical sales and marketing organizations must recalibrate value propositions, emphasizing how autoinjector-based biosimilars can streamline clinic workflows, reduce administration time, and potentially lower indirect costs associated with in-clinic infusions or nurse-led injections.

For technology vendors supplying analytical equipment, laboratory instrumentation, and validation services, the expansion of device-based biosimilars like SteQeyma’s autoinjector implies continuous demand for stability studies, extractables and leachables testing, device robustness evaluations, and in-process control analytics. Contract laboratories and CROs in Europe can leverage this trend by offering integrated packages covering both biologic characterization and device testing, positioning themselves as end-to-end partners for biosimilar developers. Furthermore, investment in laboratory automation and robotics that support high-throughput testing of device batches can improve turnaround times and reduce costs, improving competitiveness in a market where price pressures are intense.

In the medium term, the positive CHMP opinion may have knock-on effects for hospital tenders and regional procurement strategies aiming to standardize on a limited number of device platforms to simplify training and stock management. If SteQeyma wins final marketing authorization for the autoinjector and gains broad formulary acceptance, other companies may accelerate their own autoinjector or pen platform investments to avoid losing share in key therapeutic categories. This dynamic could stimulate additional capital expenditure on pharmaceutical process machinery, fill-finish lines tailored for pre-filled devices, and secondary packaging lines configured for multiple presentation types. Stakeholders across the European pharma manufacturing ecosystem will therefore be monitoring how rapidly Celltrion moves from positive opinion to commercial roll-out and how health systems respond in terms of contracting, guidelines, and prescribing patterns.